Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of KW-6500 when administered
as long-term subcutaneous self-injections in Parkinson's disease patients with motor response
complications on levodopa therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.